<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html lang="en">

<head>
  <title>H5 Adult - Chiron Study of Bird Flu Vaccine - Full Text View - ClinicalTrials.gov</title>
    <meta name="robots" content="noindex,nofollow"/>
    <meta http-equiv="Content-Type" content="text/html;charset=UTF-8"/>
    <link href="/ct2/show/NCT00280033" rel="canonical"/>
    <link href="/ct2/html/images/frame/icon.ico" rel="SHORTCUT ICON"/>
  <link href="/ct2/html/images/frame/ct.css" type="text/css" rel="stylesheet"/>
  <script type="text/javascript" src="/ct2/html/images/frame/ct.js" language="JavaScript">
  </script>
</head>

<body style="min-width:720px; margin-left:0px; margin-right:0px; margin-top:0px" onload="doLoadActions();">

<!-- small_banner -->
<div class="skip"><a href="#MainContent">Skip to Main Content</a></div>

<table class="layout_table banner_color" cellspacing="0" cellpadding="0" border="0" width="100%">
  <tr>
    <td align="left" style="padding:6px" nowrap>
      <a title="Show Home Page" href="/ct2/home">
        <img alt="ClinicalTrials.gov" src="/ct2/html/images/frame/small_title.gif" border="0"/>
      </a>
    </td>

    <td class="header3" align="right" style="padding:3px 12px 3px 3px;" nowrap>
            <a style="margin-left:1em;" title="Show Home Page" href="/ct2/home">Home</a>
            <a style="margin-left:1em;" title="Show Search Page" href="/ct2/search">Search</a>
            <a style="margin-left:1em;" title="Show Study Topics Page" href="/ct2/search/browse">Study Topics</a>
            <a style="margin-left:1em;" title="Show Glossary Page" href="/ct2/info/glossary">Glossary</a>
            <br/>
      <form method="get" action="/ct2/results" style="margin-top:0.5ex; margin-bottom:0px;">
        <input class="body3" type="text" name="term" alt="Quick Search" title="Quick Search" value="" size="30" maxlength="250"/>
        <input class="header3" type="submit" alt="Search" value="Search"/>
        
      </form>
    </td>
  </tr>
</table>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<a name="MainContent" id="skipnav"></a>


<!-- above_tabs -->
<div class="show_back_color">
<br/>


</div>








<!-- tabs -->
<div class="show_back_color header3">
<table class="layout_table" cellpadding="0" cellspacing="0" border="0">
  <tr valign="bottom">
            <td valign="bottom"><img style="width:20px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="fore_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_fore.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_fore.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5ex 1.0em" nowrap >
            <span class="header2">Full Text View</span>
          </td>
          <td align="right"><img style="width:2px; height:4ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img width="1" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td/>
          <td align="right"><img width="2" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Tabular View Page" href="/ct2/show/record/NCT00280033" >Tabular View</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show No Study Results Posted Page" href="/ct2/show/results/NCT00280033"  style="color:#666666" >No Study Results Posted</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td valign="bottom"><img style="width:50px; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
            <td>
      <table class="back_tab_color layout_table" cellpadding="0" cellspacing="0" border="0">
        <tr>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_left_back.gif" alt=""/></td>
          <td valign="top"><img style="width:100%; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
          <td class="show_back_color"><img width="6" height="6" src="/ct2/html/images/tabs/upper_right_back.gif" alt=""/></td>
        </tr>
        <tr>
          <td align="left"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/left.gif" alt=""/></td>
          <td valign="top" style="padding:0.5px 0.5em" nowrap>
            <a title="Show Related Studies Page" href="/ct2/show/related/NCT00280033" >Related Studies</a>
          </td>
          <td align="right"><img style="width:2px; height:3ex;" src="/ct2/html/images/tabs/right.gif" alt=""/></td>
        </tr>
        <tr>
          <td valign="top" colspan="3"><img width="100%" height="2" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        </tr>
      </table>
    </td>
        <td valign="bottom"><img style="width:10px; height:2px;" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
        <td valign="bottom" width="100%"><img style="width:100%; height:2px" src="/ct2/html/images/tabs/top.gif" alt=""/></td>
  </tr>
</table>
</div>

<!-- Title section -->
<div class="indent3" align="center">

    <div class="header1" style="margin-top:3ex;">H5 Adult - Chiron Study of Bird Flu Vaccine</div>
  
      <div class="header2" style="margin-top:2ex; color:  red  ">
    This study has been completed.
  </div>
      
  
  <div style="margin-top:2ex">
    First Received: January 19, 2006 &nbsp;
          Last Updated: August 26, 2010 &nbsp;
      <a href="/ct2/archive/NCT00280033"
        title="Historical versions of study NCT00280033 on ClinicalTrials.gov Archive Site"
        onclick="openNewWindow('/ct2/archive/NCT00280033'); return false;">History of Changes</a>
      </div>

  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="50%" style="margin:2ex 0;">

        <tr>
      <th align="right" nowrap class="header3 pale_banner_color"> Sponsor: </th>
      <td align="left" nowrap class="body2"> <a href="/ct2/bye/BQoPWw4lZX-i-iSxuQ7Ge6YxuQ7Ju6c9c." onclick="openNewWindow('/ct2/bye/BQoPWw4lZX-i-iSxuQ7Ge6YxuQ7Ju6c9c.'); return false">National Institute of Allergy and Infectious Diseases (NIAID)</a> </td>
    </tr>
    
    
        <tr>
      <th align="right" nowrap class="header3 pale_banner_color">Information provided by: </th>
      <td align="left" nowrap class="body2">National Institute of Allergy and Infectious Diseases (NIAID)</td>
    </tr>
    
    <tr>
      <th align="right" nowrap class="header3 pale_banner_color">ClinicalTrials.gov Identifier: </th>
      <td align="left" nowrap class="body2">NCT00280033</td>
    </tr>

  </table>

</div>
  
<!-- purpose_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Purpose</span>

<div class="indent2" style="margin-top:2ex">

  <div class="body3"><p style="margin-top:1ex; margin-bottom:1ex;">This study is will gather critical information on the safety, tolerability, and the immunogenicity (capability of causing an immune response) of A/H5N1 (Bird flu) virus vaccine in healthy adults.  Up to 400 healthy adults, aged 18 to 64, will participate.  Each subject will participate for about 7 months and will be randomly placed in one of several different study groups receiving a different dose of vaccine or placebo.  All subjects will receive two injections of their assigned study product, about 28 days apart, in the muscle.  Subjects will keep a journal of their temperature and any adverse effects between study visits.  A small amount of blood will also be drawn before the first injection, 7 days after each injection, 1 month after the first injection, and 1 and 6 months after the second injection.</p></div><br/>

    <!-- condition, intervention, phase summary table -->
  <div align="center">
  <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="80%">
    <tr align="left">
            <th class="header3 pale_banner_color">
        <a href="/ct2/help/conditions_desc" title="Help on Conditions field" onclick="openPopupWindow('/ct2/help/conditions_desc',false); return false;">Condition</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">Intervention</a>
      </th>
                  <th class="header3 pale_banner_color">
        <a href="/ct2/help/phase_desc" title="Help on Phase field" onclick="openPopupWindow('/ct2/help/phase_desc',false); return false;">Phase</a>
      </th>
          </tr>
    <tr align="left" valign="top">
            <td class="body3" nowrap>
                Influenza<br/>
              </td>
                  <td class="body3" nowrap>
                Biological: Aluminum hydroxide<br/>
                Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)<br/>
                Biological: MF-59<br/>
                Drug: Placebo<br/>
              </td>
                  <td class="body3" nowrap>
                Phase I<br/>
                Phase II<br/>
              </td>
          </tr>
  </table>
  </div>
  <br/>
  
  
  <table class="layout_table" style="margin-bottom:2ex;" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Study Type:</td>
      <td style="padding-left:1em">
        Interventional
              </td>
    </tr>
            <tr valign="top">
      <td nowrap>Study Design:</td>
      <td style="padding-left:1em">Allocation:&#160;Randomized<br/>Control:&#160;Placebo&#160;Control<br/>Endpoint&#160;Classification:&#160;Safety/Efficacy&#160;Study<br/>Intervention&#160;Model:&#160;Parallel&#160;Assignment<br/>Masking:&#160;Double&#160;Blind&#160;(Subject,&#160;Investigator)<br/>Primary&#160;Purpose:&#160;Prevention</td>
    </tr>
            <tr valign="top">
      <td nowrap style="padding-top:2ex">Official Title:</td>
      <td style="padding-left:1em; padding-top:2ex">A Randomized, Placebo-Controlled, Phase I/II, Dose-Ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or Combined With Adjuvants in Healthy Adults</td>
    </tr>
      </table>

    <!-- NLM links -->
  <br/>
  <div class="header3">Resource links provided by NLM:</div>
  <br/>
  <div class="indent3">

  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a href="http://www.nlm.nih.gov/medlineplus/" title="MedlinePlus site" onclick="openNewWindow('http://www.nlm.nih.gov/medlineplus/'); return false">MedlinePlus</a> related topics:
            <a style="padding-left:0.5em;" href="/ct2/bye/ZQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9pQ1y56NaLXNkWd7E." title="Bird&#160;Flu at MedlinePlus site" onclick="openNewWindow('/ct2/bye/ZQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9pQ1y56NaLXNkWd7E.'); return false">Bird&#160;Flu</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/fQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9Ndo8uQoPmdt." title="Flu at MedlinePlus site" onclick="openNewWindow('/ct2/bye/fQoPWw4lZX-i-iSxudhWudNzlXNiZip9m67PvQ7xzwhaLwS9Ndo8uQoPmdt.'); return false">Flu</a>
          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a href="http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp" title="Drug Information Portal" onclick="openNewWindow('http://druginfo.nlm.nih.gov/drugportal/drugportal.jsp'); return false">Drug Information</a> available for:
            <a style="padding-left:0.5em;" href="/ct2/bye/XQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789V7aLd7zui7WfQoz5wN9OQ7Pz." title="Aluminum&#160;hydroxide at ChemIDplus site" onclick="openNewWindow('/ct2/bye/XQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789V7aLd7zui7WfQoz5wN9OQ7Pz.'); return false">Aluminum&#160;hydroxide</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/MQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789C8BfgC5." title="MF&#160;59 at ChemIDplus site" onclick="openNewWindow('/ct2/bye/MQoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789C8BfgC5.'); return false">MF&#160;59</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/4QoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789V7aU67a5wNGW6V." title="Algeldrate at ChemIDplus site" onclick="openNewWindow('/ct2/bye/4QoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789V7aU67a5wNGW6V.'); return false">Algeldrate</a>
                <a style="padding-left:0.5em;" href="/ct2/bye/3QoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789V7aLd7zui7W." title="Aluminum at ChemIDplus site" onclick="openNewWindow('/ct2/bye/3QoPWw4lZXcPSi7iedN6ZXNxvdDxuQ7Ju6c9cXcPSi7iEd-yWB7EZ6o35Q1yzB-VuQUgEscxkd789V7aLd7zui7W.'); return false">Aluminum</a>
          </div>
  
  <a href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>


  
  <br/>
  
  </div>
  
    <!-- more details -->
  <br/>
  <div class="header3">Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):</div>
  <br/>
  <div class="indent3">

        <!-- primary outcomes -->
    <div class="body3">Primary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Adverse event or SAE information (solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessments). [&nbsp;Time&nbsp;Frame:&nbsp;Adverse events will be collected through 28 days following the second dose of vaccine (approximately Day 56). Serious adverse events will be collected throughout the study through Day 208.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;Yes&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Geometric mean titer and frequency of 4-fold or greater increases in serum hemagglutination inhibition (HAI) antibody titers in each group 28 days after receipt of the second dose of vaccine. [&nbsp;Time&nbsp;Frame:&nbsp;Approximately Day 56.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers in each group 28 days after receipt of the second dose of vaccine. [&nbsp;Time&nbsp;Frame:&nbsp;Approximately Day 56.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Proportion of subjects in each group achieving a serum neutralizing antibody titer ratio of 1:40 against the influenza A/H5N1 virus 28 days following second dose of vaccine. [&nbsp;Time&nbsp;Frame:&nbsp;Approximately Day 56.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Proportion of subjects in each dose group achieving a serum hemagglutination (HAI) antibody titer of 1:40 against the influenza A/H5N1 virus 28 days after receipt of the second dose of vaccine. [&nbsp;Time&nbsp;Frame:&nbsp;Approximately Day 56.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<br/>
            </ul>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="body3">Secondary Outcome Measures:
      <ul style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Development of serum antibody responses against antigenically drifted variants of H5N1influenza virus. [&nbsp;Time&nbsp;Frame:&nbsp;Blood samples for serum assays will be collected at Day 0 and at Days 28, 56, and 208 after the first immunization.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Geometric mean titer and the frequency of 4-fold or greater increases in serum HAI antibody titers 1 month after receipt of each dose, and 7 months after receipt of the first dose of vaccine. [&nbsp;Time&nbsp;Frame:&nbsp;Blood samples for serum assays will be collected at Day 0 and at Days 28, 56, and 208 after the first immunization.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<br/>
            <li style="margin-top:0.7ex;">Geometric mean titer and the frequency of 4-fold or greater increases in neutralizing antibody titers in each group 1 month after receipt of each dose, and 7 months after receipt of the first dose of vaccine. [&nbsp;Time&nbsp;Frame:&nbsp;Blood samples for serum assays will be collected at Day 0 and at Days 28, 56, and 208 after the first immunization.&nbsp;] [&nbsp;Designated&nbsp;as&nbsp;safety&nbsp;issue:&nbsp;No&nbsp;]<br/>
            </ul>
    </div>
    <br/>
    
    
    <table class="layout_table" style="margin-bottom:3ex;" cellpadding="0" cellspacing="0" border="0">
            <tr valign="top">
        <td nowrap> Enrollment:</td>
        <td style="padding-left:1em">394</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Start Date:</td>
        <td style="padding-left:1em">February 2006</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Study Completion Date:</td>
        <td style="padding-left:1em">November 2006</td>
      </tr>
                  <tr valign="top">
        <td nowrap> Primary Completion Date:</td>
        <td style="padding-left:1em">November 2006 (Final data collection date for primary outcome measure)</td>
      </tr>
          </table>

        <!-- arms and groups table -->
    <div align="center">
    <table class="data_table" cellspacing="0" cellpadding="5" border="1" width="100%">
      <tr align="left">
        <th class="header3 pale_banner_color">
          <a href="/ct2/help/arm_group_desc" title="Help on Arm Group field" onclick="openPopupWindow('/ct2/help/arm_group_desc',false); return false;">
             Arms           </a>
        </th>
                <th class="header3 pale_banner_color">
          <a href="/ct2/help/interventions_desc" title="Help on Interventions field" onclick="openPopupWindow('/ct2/help/interventions_desc',false); return false;">
            Assigned Interventions
          </a>
        </th>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          1: Experimental
<div class="indent2" style="margin-top:0.5ex">7.5 mcg plus MF59 administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)</li>
<li>Biological: MF-59</li>
</ul>
</div>
        </td>
                <td class="body3">
                      Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)
<div class="indent2" style="margin-top:0.5ex">Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.</div>
                      Biological: MF-59
<div class="indent2" style="margin-top:0.5ex">Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          2: Experimental
<div class="indent2" style="margin-top:0.5ex">7.5 mcg plus aluminum hydroxide administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Biological: Aluminum hydroxide</li>
<li>Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)</li>
</ul>
</div>
        </td>
                <td class="body3">
                      Biological: Aluminum hydroxide
<div class="indent2" style="margin-top:0.5ex">Provided in vials that contain 0.8 mL volume per vial.</div>
                      Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)
<div class="indent2" style="margin-top:0.5ex">Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          4: Experimental
<div class="indent2" style="margin-top:0.5ex">15 mcg plus MF59 administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)</li>
<li>Biological: MF-59</li>
</ul>
</div>
        </td>
                <td class="body3">
                      Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)
<div class="indent2" style="margin-top:0.5ex">Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.</div>
                      Biological: MF-59
<div class="indent2" style="margin-top:0.5ex">Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          6: Experimental
<div class="indent2" style="margin-top:0.5ex">30 mcg alone administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)</div>
        </td>
                <td class="body3">
                      Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)
<div class="indent2" style="margin-top:0.5ex">Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          8: Experimental
<div class="indent2" style="margin-top:0.5ex">45 mcg alone administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)</div>
        </td>
                <td class="body3">
                      Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)
<div class="indent2" style="margin-top:0.5ex">Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          9: Placebo Comparator
<div class="indent2" style="margin-top:0.5ex">Saline administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Drug: Placebo</div>
        </td>
                <td class="body3">
                      Drug: Placebo
<div class="indent2" style="margin-top:0.5ex">Saline placebo.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          7: Experimental
<div class="indent2" style="margin-top:0.5ex">30 mcg plus aluminum hydroxide administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Biological: Aluminum hydroxide</li>
<li>Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)</li>
</ul>
</div>
        </td>
                <td class="body3">
                      Biological: Aluminum hydroxide
<div class="indent2" style="margin-top:0.5ex">Provided in vials that contain 0.8 mL volume per vial.</div>
                      Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)
<div class="indent2" style="margin-top:0.5ex">Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          5: Experimental
<div class="indent2" style="margin-top:0.5ex">15 mcg plus aluminum hydroxide administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Interventions:<ul style="margin-top:0.5ex">
<li>Biological: Aluminum hydroxide</li>
<li>Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)</li>
</ul>
</div>
        </td>
                <td class="body3">
                      Biological: Aluminum hydroxide
<div class="indent2" style="margin-top:0.5ex">Provided in vials that contain 0.8 mL volume per vial.</div>
                      Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)
<div class="indent2" style="margin-top:0.5ex">Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.</div>
                  </td>
              </tr>
            <tr align="left" valign="top">
        <td class="body3">
          3: Experimental
<div class="indent2" style="margin-top:0.5ex">15 mcg alone administered on days 0 and 28.</div>
<div class="indent2" style="margin-top:0.5ex">Intervention: Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)</div>
        </td>
                <td class="body3">
                      Biological: Inactivated Influenza A/H5N1 Vaccine (Chiron)
<div class="indent2" style="margin-top:0.5ex">Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.</div>
                  </td>
              </tr>
          </table>
    </div>
    <br/>
    
    
    <a name="desc" id="desc"></a>

    
    
        <!-- detailed description -->
    <span class="header3">Detailed Description:</span>
    <div class="body3"><p style="margin-top:1ex; margin-bottom:1ex;">The emergence of novel influenza A virus strains in humans (including subtype A/H5N1, H7N7 H9N2 viruses) has added urgency to ongoing efforts to develop plans for responding to potential pandemic situations. This study compares the safety, reactogenicity, and immunogenicity of increasing doses of monovalent subvirion influenza A/H5N1 virus vaccine administered by intramuscular (IM) injection to healthy adults alone or combined with the adjuvants aluminum hydroxide or MF59. The primary objectives are to determine: the dose-related safety of subvirion inactivated H5N1vaccine with and without adjuvants in healthy adults; the dose-related immunogenicity of subvirion inactivated H5N1vaccine with and without adjuvants in healthy adults approximately 1 month following receipt of 2 vaccine doses; to provide information for the selection of the best dosage level for further studies. The secondary objectives are to evaluate dose-related immunogenicity and the percent of subjects responding about 1 and 7 months after the first vaccination. The primary endpoints are: adverse event (AE) or serious adverse event (SAE) information; proportion of subjects in each dose group achieving a serum neutralizing antibody titer of 1:40 against the influenza A/H5N1 virus 28 days after receipt of the second dose of vaccine; proportion of subjects in each dose group achieving a serum hemagglutination (HAI) antibody titer of 1:40 against the influenza A/H5N1 virus 28 days after receipt of the second dose of vaccine; geometric mean titer (GMT) and frequency of 4-fold or greater increases in neutralizing antibody titers in each group 28 days after receipt of the second dose of vaccine; geometric mean titer and frequency of 4-fold or greater increases in serum HAI antibody titers in each group 28 days after receipt of the second dose of vaccine. The secondary endpoints are: GMT and frequency of 4-fold or greater increases in neutralizing antibody titers in each group 1 month and 7 months after receipt of the first dose of vaccine; geometric mean titer and frequency of 4-fold or greater increases in serum HAI antibody titers in each group 1 month and 7 months after receipt of the first dose of vaccine; development of serum antibody responses against antigenically drifted variants of H5N1 influenza virus. The primary outcome measures will be the frequencies and severities of AEs in each group and the proportions of subjects who achieve a serum neutralizing antibody titer of 1:40 against the influenza A/H5N1 virus on Day 56. About 390 healthy adults, 18 to 64 years old, inclusive, will be enrolled into this multicenter, randomized, placebo-controlled, dose-ranging clinical trial. Nine groups of randomized subjects will receive two doses of saline placebo or influenza A/H5N1 vaccine at 45, 30, or 15 micrograms; or influenza A/H5N1 vaccine at 15 or 7.5 micrograms with MF59; or influenza A/H5N1 vaccine with aluminum hydroxide at 30, 15, or 7.5 micrograms (N=30, 60 or 90/vaccine dose group total 390). Laboratory safety profile blood will be drawn prior to the first immunization. Subjects will receive 2 doses approximately 28 days apart. Subjects will be observed after inoculation and maintain a memory aid for 7 days afterwards. Subjects will be telephoned 1 to 3 days after vaccination for AE assessment, and they will return to the clinic on Day 7 for AE and concomitant medication assessment, targeted physical examination, safety laboratory tests and a review of the memory aid.  Telephone calls assessing AEs will be performed after each vaccination. Serum for safety laboratory tests will be obtained prior to and approximately 7 days after first and second immunizations. Immunogenicity serum will be obtained prior to immunization, approximately 1 month after first immunization and approximately 1 month and 6 months after second immunization. This study is linked to DMID protocols 06-0005, 05-0144, 05-0145, and 07-0022.</p></div>
        
  </div>
  
</div>
</div>
  
<!-- eligibility_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
  <img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Eligibility</span><br/>

  <br/>
  <div class="indent2">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0">
            <tr>
        <td nowrap>Ages Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">18 Years to 64 Years</td>
      </tr>
                  <tr>
        <td nowrap>Genders Eligible for Study: &nbsp; </td>
        <td style="padding-left:1em">Both</td>
      </tr>
                  <tr>
        <td nowrap>Accepts Healthy Volunteers: &nbsp; </td>
        <td style="padding-left:1em">Yes</td>
      </tr>
                </table>

    
        <div class="header3" style="margin-top:2ex">Criteria</div>
    <div class="indent2"><p style="margin-top:0ex; margin-bottom:1ex;">Inclusion Criteria:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Healthy male or nonpregnant female (as indicated by a negative urine pregnancy test immediately prior to vaccine administration) between the ages of 18 and 64 years, inclusive.</li>
<li style="margin-top:0.7ex;">Women of childbearing potential (not surgically sterile or post menopausal for greater than or equal to one year) must agree to practice adequate contraception (i.e., barrier method, abstinence, and licensed hormonal methods) for the entire study period.</li>
<li style="margin-top:0.7ex;">Is in good health, as determined by vital signs (heart rate, blood pressure, oral temperature), medical history and a targeted physical examination based on medical history.</li>
<li style="margin-top:0.7ex;">Subjects should have normal safety laboratory values (Hgb, WBC, Plt, ALT, and creatinine) prior to the first immunization.</li>
<li style="margin-top:0.7ex;">Able to understand and comply with planned study procedures.</li>
<li style="margin-top:0.7ex;">Provides written informed consent prior to initiation of any study procedures.</li>
</ul>
<p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
<ul style="margin-top:1ex; margin-bottom:1ex;">
<li style="margin-top:0.7ex;">Has a known allergy to eggs or other components of the vaccine or latex.</li>
<li style="margin-top:0.7ex;">Has a positive urine pregnancy test prior to vaccination (if female of childbearing potential) or women who are breastfeeding.</li>
<li style="margin-top:0.7ex;">Is undergoing immunosuppression as a result of an underlying illness or treatment.</li>
<li style="margin-top:0.7ex;">Has an active neoplastic disease or a history of any hematologic malignancy.</li>
<li style="margin-top:0.7ex;">Is using oral or parenteral steroids, high-dose inhaled steroids (greater than 800 micrograms/day of beclomethasone dipropionate or equivalent) or other immunosuppressive or cytotoxic drugs (nasal and topical steroids are allowed).</li>
<li style="margin-top:0.7ex;">Has a history of receiving immunoglobulin or other blood products within the 3 months prior to vaccination in this study.</li>
<li style="margin-top:0.7ex;">Has received any other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to vaccination in this study.</li>
<li style="margin-top:0.7ex;">Has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses (this includes, but is not limited to: known chronic liver disease, significant renal disease, unstable or progressive neurological disorders, diabetes mellitus, and transplant recipients).</li>
<li style="margin-top:0.7ex;">Has a history of severe reactions following immunization with contemporary influenza virus vaccines.</li>
<li style="margin-top:0.7ex;">Has an acute illness, including an oral temperature greater than 100.4 degrees F, within 1 week of vaccination.</li>
<li style="margin-top:0.7ex;">Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to vaccination in this study, or expects to receive an experimental agent during the 7-month study period.</li>
<li style="margin-top:0.7ex;">Has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.</li>
<li style="margin-top:0.7ex;">Participated in H5 vaccine study in the past.</li>
<li style="margin-top:0.7ex;">Known current HIV, hepatitis B (HBsAg) or hepatitis C infection.</li>
<li style="margin-top:0.7ex;">History of alcohol or drug abuse in the last 5 years.</li>
<li style="margin-top:0.7ex;">Planned travel outside the US between vaccination and the second study visit.</li>
<li style="margin-top:0.7ex;">History of Guillain-Barre.</li>
</ul></div>
    
  </div>

</div>

  
<!-- location_section -->
<div class="indent1" style="margin-top:3ex">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; Contacts and Locations</span><br/>

<div class="indent2" style="margin-top:2ex">

    Please refer to this study by its ClinicalTrials.gov identifier: NCT00280033<br/>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
  <a name="locn" id="locn"></a>

  
  
    <div class="header3" style="margin-top:2ex">Locations</div>
  <table class="layout_table indent2" cellspacing="0" cellpadding="0" border="0">
            <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, California</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Stanford University</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Stanford, California, United States, 94305-5208  </td></tr>
                    <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, Missouri</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Saint Louis University</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>St. Louis, Missouri, United States, 63110-0250  </td></tr>
                    <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, Ohio</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Cincinnati Children's Hospital Medical Center</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Cincinnati, Ohio, United States, 45229-3039  </td></tr>
                    <tr><td colspan="2" class="header3" style="padding-top:2ex" nowrap>United States, Tennessee</td></tr>
            <tr>
            <td style="padding:1ex 1em 0px 2em" nowrap>Vanderbilt University</td>
                </tr>
        <tr><td colspan="2" style="padding-left:4em" nowrap>Nashville, Tennessee, United States, 37232  </td></tr>
              </table>
  
  
  <!-- sponsors -->
    <div class="header3" style="margin-top:2ex">Sponsors and Collaborators</div>
    <div class="indent2" style="margin-top:1ex"><a href="/ct2/bye/BQoPWw4lZX-i-iSxuQ7Ge6YxuQ7Ju6c9c." onclick="openNewWindow('/ct2/bye/BQoPWw4lZX-i-iSxuQ7Ge6YxuQ7Ju6c9c.'); return false">National Institute of Allergy and Infectious Diseases (NIAID)</a></div>
    
  <!-- investigators -->
  

</div>
</div>

<!-- more_info_section -->
<div class="indent1" style="margin-top:3ex; border:1px solid white">
<img src="/ct2/html/images/frame/triangle.gif" alt=""/><span class="header2">&nbsp; More Information</span>

<div class="indent2">
  <br/>


  
    No publications provided  by National Institute of Allergy and Infectious Diseases (NIAID) <br/>
  <br/>
  
    Additional publications automatically indexed to this study by National Clinical Trials Identifier (NCT ID):
  <div class="indent2">
        <div style="margin-top:2ex">
            <a href="/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJSg0t-g0V." title="Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008 Mar 1;197(5):667-75." onclick="openNewWindow('/ct2/bye/zQoPWw4lZX-i-iSxuBcyeXNxvdDxuQ7Ju6c9cXcHuioyzTp9ai7HSTDxNBciescgm64LD61PSQ7Hc6D65B0LVi7yg67VN6h9Ei4L3BUgWwNG0iY6vQ1gW1-He6oR9RCJSg0t-g0V.'); return false">Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HK, Graham IL, Noah DL, He F, Hill H. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis. 2008 Mar 1;197(5):667-75.</a>
          </div>
      </div>
  <br/>
  
  
  <table class="layout_table" style="margin-top:1ex" cellpadding="0" cellspacing="0" border="0">
        <tr valign="top">
      <td nowrap>Responsible Party:</td>
      <td style="padding-left:1em">HHS/NIAID/DMID ( Robert Johnson )</td>
    </tr>
        <tr valign="top">
      <td nowrap>ClinicalTrials.gov Identifier:</td>
      <td style="padding-left:1em">
        <a title="Current version of study NCT00280033 on ClinicalTrials.gov" href="http://clinicaltrials.gov/ct2/show/NCT00280033">NCT00280033</a> &nbsp; &nbsp;
        <a href="/ct2/archive/NCT00280033"
          title="Historical versions of study NCT00280033 on ClinicalTrials.gov Archive Site"
          onclick="openNewWindow('/ct2/archive/NCT00280033'); return false;">History of Changes</a>
      </td>
    </tr>
            <tr valign="top">
      <td nowrap>Other Study ID Numbers:</td>
      <td style="padding-left:1em">04-062</td>
    </tr>
            <tr valign="top">
      <td nowrap>Study First Received:</td>
      <td style="padding-left:1em">January 19, 2006</td>
    </tr>
                <tr valign="top">
      <td nowrap>Last Updated:</td>
      <td style="padding-left:1em">August 26, 2010</td>
    </tr>
            <tr valign="top">
      <td nowrap>Health Authority:</td>
      <td style="padding-left:1em">United States: Food and Drug Administration; &nbsp; United States: Federal Government; &nbsp; United States: Institutional Review Board</td>
    </tr>
      </table>

  
  <!-- keywords -->
    <br/>
  Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    H5N1, Influenza, vaccine<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  <!-- mesh terms -->
    <br/>
  Additional relevant MeSH terms:
  <div class="indent3">
    <table class="layout_table" cellpadding="0" cellspacing="0" border="0" width="100%">
      <tr valign="top">
        <td width="50%">
                    Influenza, Human<br/>
                    Orthomyxoviridae Infections<br/>
                    RNA Virus Infections<br/>
                    Virus Diseases<br/>
                    Respiratory Tract Infections<br/>
                    Respiratory Tract Diseases<br/>
                    Aluminum Hydroxide<br/>
                  </td>
                <td width="50%" style="padding-left:1em">
                    Antacids<br/>
                    Molecular Mechanisms of Pharmacological Action<br/>
                    Pharmacologic Actions<br/>
                    Adjuvants, Immunologic<br/>
                    Immunologic Factors<br/>
                    Physiological Effects of Drugs<br/>
                  </td>
              </tr>
    </table>
  </div>
  
  
  <br/>

    <span class="body3">ClinicalTrials.gov processed this record on March 02, 2011</span><br/>
  
  <br/>

</div>
</div>


<!-- Footer -->
<div class="skip"><a href="#MainContent">Back to top of Main Content</a></div>

<img width="100%" height="3" src="/ct2/html/images/frame/bar.gif" alt=""/><br/>

<div align="center" class="footer">
  <br/>
  <a href="/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00280033" onclick="openPopupWindow('/ct2/helpdesk?hd_url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT00280033',true); return false;">Contact Help Desk</a><br/>
  <a href="http://www.lhncbc.nlm.nih.gov">Lister Hill National Center for Biomedical Communications</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a>,<br/>
  <a href="http://www.nih.gov/">U.S. National Institutes of Health</a>,&nbsp;
  <a href="http://www.hhs.gov/">U.S. Department of Health &amp; Human Services</a>,<br/>
  <a href="http://www.usa.gov/">USA.gov</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/copyright.html">Copyright</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/privacy.html">Privacy</a>,&nbsp;
  <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a>,&nbsp;
  <a href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a><br/>

  <br/>
  <a href="http://www.nih.gov/"><img alt="U.S. National Institutes of Health" src="/ct2/html/images/frame/nih_logo.gif" border="0"/></a>
  <a href="http://www.nlm.nih.gov/"><img alt="U.S. National Library of Medicine" src="/ct2/html/images/frame/nlm_logo.gif" border="0"/></a>
  <a href="http://www.hhs.gov/"><img alt="U.S. Department of Health &amp; Human Services" src="/ct2/html/images/frame/hhs_logo.gif" border="0"/></a>

  <br/>
  <br/>
  <br/>
  <br/>
  <a href="/ct2/crawl" class="skip">Links to all studies - primarily for crawlers</a>
</div>

<!-- 2011:03:04 02:34:58.647  RRd0VFK:SRd0P7v:I4Ya2XK -->
</body>
</html>
